Daily energy expenditure in free-living heart failure patients. Am. J. Physiol.
35): E469-E475, 1,997.-We examined the hypothesis that weight loss in heart failure patients is associated with elevated daily energy expenditure.
Twelve cachectic patients [age = 73 t 6 yr; weight loss = 15 5 6 kg; body mass index (BMI) = 21 t 5 kg/m"], 13 noncachectic patients (age = 67 t 5 yr; BMI = 27 t 5 kg/m"), and 50 healthy elderly controls (age = 69 ? 6 yr; BMI = 26 t 4 kg/m2) were studied. Daily energy expenditure and it components were measured using doubly labeled water and indirect calorimetry and body composition by dual-energy X-ray absorptiometry.
Fat mass and fat-free mass were lower (P < 0.05) in cachectic patients compared with noncachectic patients and healthy controls. Daily energy expenditure was lower (P < 0.05) in cachectic patients (1,870 2 347 kcal/day) compared with noncachectic patients (2,349 2 545 kcal/day) and healthy controls (2,543 t 449 kcal/day). Differences in daily energy expenditure were primarily due to lower (P < 0.05) physical activity energy expenditure in cachectic (269 t_ 307 kcal/day) and noncachectic patients (416 t 361 kcal/day) compared with healthy controls (728 5 374 kcal/day). A lower (P < 0.05) resting energy expenditure was also noted in cachectic patients (1,414 t 210 kcal/day) compared with noncachectic patients (1,698 t 252 kcal/day) and healthy controls (1,561 _t 223 kcal/day). These findings show that daily energy expenditure is not higher, but significantly lower, in cachectic heart failure patients due to lower physical activity and resting energy expenditure.
These results argue against the hypothesis that an abnormally elevated daily energy expenditure is associated with weight loss in heart failure. cardiac cachexia; doubly labeled water PATIENTS WITH CHRONIC heart failure frequently experience significant weight loss during the course of the disease (3, 4) . Weight loss may lead to cardiac atrophy and further decompensation (1). Moreover, weight loss is associated with increased mortality (13, 28) . At present, the etiology of weight loss in patients with heart failure is not understood.
Weight loss results from an imbalance between daily energy intake and daily energy expenditure. Whereas measurement of energy intake is subject to error from recording inaccuracies (10, 25>, assessment of energy expenditure is more reliable. No study, however, has measured daily energy expenditure in free-living heart failure patients. Thus it is unknown whether reduced energy intake, elevated energy expenditure, or a combination of both factors contributes to weight loss in heart failure.
Previous investigations examining energy expenditure in heart failure patients have focused on resting energy expenditure because of its large contribution (60-80%) to daily energy expenditure. These studies found elevated resting energy expenditure in heart failure patients compared with healthy controls (23, 24) . Although these findings appear to support the hypothesis that elevated energy expenditure contributes to weight loss in heart failure patients (20), resting energy expenditure represents only one component of daily energy expenditure. The remaining and most variable fraction of daily energy expenditure, which consists largely of physical activity energy expenditure, has not been directly measured in free-living heart failure patients. Thus, to support the hypothesis that elevated energy expenditure predisposes to weight loss in heart failure, it must be demonstrated that daily energy expenditure is elevated.
Assessment of daily energy expenditure in free-living humans, until recently, has been problematic due to methodological limitations. The availability of the doubly labeled water technique provides a method to accurately measure daily energy expenditure in freeliving humans over extended periods of time (26). This technique, in combination with indirect calorimetry, provides an assessment of daily energy expenditure and derivation of its components (resting energy expenditure and physical activity energy expenditure). The measurement of physical activity energy expenditure is particularly important, since it is the primary determinant of individual variation in daily energy expenditure in elderly individuals (10).
In the present study, we tested the hypothesis that daily energy expenditure is elevated in heart failure patients. To examine the relationship of daily energy expenditure to weight loss, we compared daily energy expenditure and its components in a cohort of cachectic heart failure patients with noncachectic patients and healthy controls. diuretics (n = 25; loo%;), vasodilators (angiotensin-converting enzyme inhibitor or hydralazine-nitrates; n = 21; 84%), and digoxin (n = 23; 88%). Two patients had non-insulin-dependent diabetes mellitus and were taking oral hypoglycemic drugs. Patients were defined by the New York Heart Association functional scale as class II (n = 9), class III (n = ll), and class IV (n = 5). Heart failure subjects were divided into cachectic and noncachectic groups. Cachexia was defined as a loss of 10% or greater of a subject's reported premorbid body weight. Twelve patients (11 men, 1 woman; 42% Caucasian, 58% African-American) were classified as cachectic and 13 as noncachectic (13 men; 62%~ Caucasian, 38% African-American).
Weight loss in 10 of the 12 cachectic patients was further verified by examination of medical records. All subjects were free of cigarette use for at least 3 mo before evaluation, although 11 patients had a history of cigarette use (4 cachectic, 7 noncachectic).
Fifty healthy, nonsmoking, elderly (48 men, 2 women; 60% Caucasian, 40% African-American) subjects were used as a nondiseased control group. Data from 28 Caucasian men were previously published (29). Healthy subjects were recruited by newspaper advertisements and community organizations. Healthy African-Americans (n = 20) were recruited from Baltimore, MD, and surrounding areas. Healthy Caucasians (n = 30) were recruited from Burlington, VT, and surrounding areas. Healthy subjects met the following criteria: 1) no symptoms or signs of heart disease or diabetes, 2) normal resting electrocardiogram, 3) normal electrocardiogram response to an exercise stress test, 4) absence of medicinal or nonmedicinal drugs that could affect cardiovascular or metabolic function, and 5) weight stability (52 kg) within 6 mo before testing. The nature, purpose, and possible risks of the study were explained to volunteers before they gave consent. This study was approved by the Committee on Human Research for the Medical Sciences of the University of Vermont and the Institutional Review Board of the University of Maryland. Experimental protocol. All measurements were made over a lo-day period. On the first day, each subject received an oral dose of doubly labeled water after a baseline urine sample was obtained. The following morning, resting energy expenditure and body composition were measured and two urine samples were collected to mark the beginning of the doubly labeled water measurement period. After being provided with a scale and instructions for recording their dietary intake, subjects left the research center and resumed their daily activities (i.e., free-living conditions). Ten days after the beginning of the doubly labeled water measurement period, subjects returned to provide two urine samples and underwent an assessment of peak oxygen consumption (vo2>. Daily energy expenditure.
Free-living daily energy expenditure was determined over a IO-day period using the doubly labeled water technique, as previously described (10). Each subject consumed a mixed, oral dose of "HZ0 and Hz'"0 (0.078 and 0.092 g/kg body mass, respectively) after providing a baseline urine sample (between the hours of 1200 and 1600). A weighed 1:400 dilution (dose:tap water) was prepared from each subject's dose, and a sample of the water used for the dilution was saved and analyzed with each subject's sample set. Two urine samples were obtained the morning after dosing to mark the beginning of the measurement period and 10 days later to mark the end (all between 0800 and 1200). All subjects were weight stable and consumed a self-selected diet during the doubly labeled water measurement period. Urine samples from both the Vermont and Maryland cohorts were stored in sealed vacutainers at -20°C until analysis in triplicate by isotope ratio mass spectrometry at the Biomedical Mass Spectrometry Facility at the University of Maryland. Samples were analyzed for isotopic enrichment of "Ha0 and H21g0 using the off-line zinc reduction procedure of Kendall and Copelan (11) and CO2 equilibration technique (5), respectively. The "H and Iti0 enrichment of samples was expressed on the relative delta per mil scale (%).
To prepare urine samples for analysis of I80 enrichment, 1 ml of sample was injected into lo-ml vacutainers along with 0.25 ml of 99.9% pure C02. In addition, l-ml aliquots of the diluted dose and water used for the dilution were similarly prepared. All samples were shaken overnight at room temperature to allow for the equilibration of I80 in the samples with injected CO2. Equilibrated COZ was injected into the mass spectrometer after separation by gas chromatography (VG Isochrom ugas, Middlewich, Cheshire, UK). The ratio of mass 46:44 was monitored using an isotope ratio mass spectrometer (Optima, Fisons Instruments, Middlewich). Quality control samples of known I80 isotopic enrichment were analyzed along with each subject's sample batch to ensure the integrity of the analysis. The average SD for 164 sets of triplicate HJHO analysis was 0.27% at a mean sample enrichment of 43.08%. The zinc reduction procedure for preparation of urine samples for "H enrichment analysis was identical to procedures previously described (10). The ratio of mass 3:2 was determined by isotope ratio mass spectrometry. A dilution of the dose given to each subject and water used for the dilution were prepared similarly and analyzed with each subject's sample set. The average SD for 172 sets of triplicate ZH20 analysis was 4.34% at a mean sample enrichment of 449.3%. The rate of carbon dioxide production (rc~o,) was calculated using Eq. 2 of Speakman et al. (27) r,loz(mollday
where N is body water pool and is equal to [Do + (D,,/DSR)]/2; Do and Dii are the HZlsO and gHZO dilution spaces in moles, respectively, Ko and KH are the turnover rates of H2180 and "HzO, respectively, in days-l, and DSR is the dilution space ratio (DH/Do). Turnover rates and zero-time enrichment of HZIHO and "H20 were determined from the slope and intercept, respectively, of the semilogarithmic plot of urinary enrichment (%) vs. time (days). Isotope dilution spaces were calculated using the equation of Coward (7). Because no differences were found among the proposed DSR of Speakman et al. (1.0427 t 0.0218), the DSR of cachectic patients (1.0408 -f 0.0159), noncachectic patients (1.0462 2 0.0118), or healthy controls (1.0488 t_ 0.0144), a fixed DSR of 1.0427 was used.
rcO, was used to calculate daily energy expenditure from Eq. 12 of Weir (30), assuming a respiratory quotient of 0.85 (2). The group mean food quotient did not differ among cachectic patients (0.87 2 0.03), noncachectic patients (0.87 t 0.03), and healthy controls (0.87 t 0.04) or from the assumed respiratory quotient. Resting energy expenditure.
Resting energy expenditure was measured in the morning (-0800) after a 12-h overnight fast in healthy volunteers and on an outpatient basis in heart failure patients at a similar time and after a similar overnight fast. Resting metabolic rate was measured by indirect calorimetry using the ventilated hood method for 45 min (Deltatrac, Sensormedics, Yorba Linda, CA). On arriving at the hospital, heart failure patients were transported to the The hydration fraction of fat-free mass, an indicator of the hydration state of the body, was calculated by dividing total body water measured with isotope dilution by fat-free mass measured with dual-energy X-ray absorptiometry. Because patients were free of edema and the hydration fraction of fat-free mass did not differ among groups (75 t 4 vs. 75 +-4 vs. 76 t 6%), we conclude that fat-free mass obtained from dual-energy X-ray absorptiometry provides a reliable measure of the metabolically active tissue in heart failure patients.
Statistics. Differences in physical and metabolic characteristics among groups were assessed by a one-way analysis of variance. If a significant group effect was found, a StudentNewman-Keuls test was used to identify the location of differences among groups. Differences in clinical characteristics between the two groups of heart failure patients were determined using an unpaired Student's t-test. Analysis of covariance was used to test for differences in peak VO, and resting energy expenditure after the effects of fat-free mass had been statistically removed. Because tumor necrosis factor-a data were not normally distributed, differences in tumor necrosis factor-a were determined by Mann-Whitney U-test. The relationship between tumor necrosis factor-a and body composition, energy expenditure, and energy intake data was determined by Spearman's rank-correlation analysis. Significance level was set at P < 0.05. All values are expressed as means t SD.
RESULTS
Tumor necrosis factor-a. Human tumor necrosis factor-c-x was measured from plasma samples by sandwich enzymelinked immunosorbent assay using commercial reagents (Endogen). All samples were analyzed in the same assay. Polystyrene plates (Maxisorp, Nunc) were coated with capture mouse monoclonal antibodies against tumor necrosis factor-cc in phosphate-buffered saline overnight at 24°C. Plates were washed five times in 50 mM tris(hydroxymethyl)aminomethane, 0.2% Tween-20 (pH 7.0-7.5) and blocked for 90 min at 25°C in a 1:l mixture of 2.5%) casein and assay buffer (phosphate-buffered saline containing 4%~ bovine serum albumin and 0.01% Thimerosal; pH 7.2-7.4). The wells were washed four times, as described above, and 50 ul of sample or standard prepared in assay buffer were incubated at 37°C for 2 h. Wells were washed four times, and 100 ul of biotinylated rabbit polyclonal anti-tumor necrosis factor-a antibody in assay buffer were added and incubated for 1 h at 25°C. Wells were washed four more times and strepavidin-peroxidase (Dako) in assay buffer was added and incubated at 25°C for 30 min. After four washes, 100 ul of a commercially prepared substrate (3,3',5,5'-tetramethylbenzidine; Dako) were added and incubated at 25°C for 30 min. The reaction was stopped with 100 ul of 2 N HCl, and the absorbance at 450 nm was read on a microplate reader (Dynatech). A curve was fit to the standards using a computer program (Deltagraph for Macintosh), and tumor necrosis factor-a concentration was calculated.
Because no differences in daily energy expenditure or its components were noted between African-American and Caucasian patients in the healthy or heart failure groups, data were pooled. Table 1 shows the physical characteristics of cachectic, noncachectic, and healthy control groups. Cachectic patients were older (P < 0.05) than noncachectic and healthy controls. No differences in height were noted among groups. Body mass index was lower (P < 0.05) in cachectic patients compared with noncachectic patients and healthy controls. Cachectic patients weighed less than the other groups due to a lower quantity of fat mass and fat-free mass (all P < 0.05). Table 2 shows the clinical characteristics of cachectic and noncachectic patients. By design, absolute weight loss and the percentage of premorbid weight lost were greater in cachectic compared with noncachectic patients (P < 0.01). The distribution of New York Heart Association classification showed that cachectic patients were more symptomatic. Ejection fraction and peak VO, did not differ among groups. Serum albumin levels were lower (P < 0.01) in cachectic compared with noncachectic patients. Peak VO,. Peak %z was assessed by a treadmill test to volitional exhaustion using an open-circuit indirect calorimetry system. Peak VO, was available for 16 heart failure patients. Table 3 shows data for the doubly labeled water experiment. Day 1 and day 10 2H20 enrichment did not differ among groups. H2180 enrichment in healthy controls was greater (P < 0.05) than in the cachectic group on day 1 and greater than in both heart failure groups on day IO. The turnover rates of 2H20 and H2180 were greater (P < 0.05) in the noncachectic group compared with the cachectic and healthy control groups. The zero-time dilution spaces of 2H20 and H2180 were lower (P < 0.05) in the cachectic group compared with noncachectic and healthy controls. rco, (corrected for fractionation) was lower (P < 0.05) in the cachectic group compared with the noncachectic and healthy control groups.
Measured and adjusted energy expenditure and energy intake data for the groups are reported in Table 4 and shown in Fig. 1 . Measured daily energy expenditure was lower (P < 0.05) in cachectic patients compared with the noncachectic and healthy control groups. Lower daily energy expenditure persisted in cachectic Values are means + SD in kcal/day. *P < 0.05 less than noncachectic and healthy controls; tP < 0.05 greater than noncachectic and cachectic patients; $P = 0.09 greater than cachectic and healthy controls.
patients after statistical control for fat-free mass (P < 0.05). Differences in daily energy expenditure were primarily due to lower (P < 0.05) free-living physical activity energy expenditure in cachectic and noncachectic patients compared with healthy controls. Lower (P < 0.05) r es ing t energy expenditure was found in cachectic patients compared with noncachectic and healthy controls. After statistical adjustment for fatfree mass, resting energy expenditure was similar between cachectic patients and healthy controls, although a trend (P < 0.09) toward an elevated resting energy expenditure was found in noncachectic patients compared with cachectic patients and healthy controls. Reported energy intake did not differ among groups.
Tumor necrosis factor-a levels were measured in a subgroup of 16 heart failure patients (8 cachectic; 8 noncachectic). No differences in tumor necrosis factor-a (274 -+ 239 vs. 205 t 275 pg/ml) were found between groups. Tumor necrosis factor-a was not related to ejection fraction (r = 0.03), New York Heart Association class (r = OX), percent weight loss (r = -0.237), fat mass (r = 0.09), fat-free mass (r = 0.X>, resting energy expenditure (r = 0.23), daily energy expenditure (r = 0.16), or reported energy intake (r = 0.00).
DISCUSSION
This is the first study to measure daily and physical activity energy expenditure in free-living heart failure patients with the use of stable isotopes. Use of the doubly labeled water technique represents a methodological advance over previous studies that have measured only resting energy expenditure in this population (23, 24). We examined the hypothesis that weight loss in heart failure patients is associated with elevated daily energy expenditure.
We did not find an elevated daily energy expenditure in cachectic patients. In fact, cachectic patients had lower daily energy expenditure compared with noncachectic patients and healthy controls. Our findings argue against the hypothesis that an abnormally elevated daily energy expenditure contributes to weight loss in heart failure.
Differences in daily energy expenditure among groups were primarily due to differences in physical activity energy expenditure (Fig. 1) . Physical activity energy expenditure was 459 and 312 kcal/day lower in cachectic and noncachectic patients, respectively, compared with healthy controls. Previous studies using motion detectors have reported reduced physical activity in heart failure patients (8, 19) . However, the present study is the first to quantify the caloric cost of physical activity in heart failure patients with the use of stable isotopes. These results underscore the importance of physical activity as a determinant of daily energy expenditure in heart failure patients and demonstrate the need to accurately measure daily energy expenditure and its components in free-living heart failure patients before drawing conclusions about the absence or presence of a hypermetabolic state. Decreased physical activity may contribute to skeletal muscle atrophy and exercise intolerance in heart failure patients (9, 15) . Elevated rates of myofibrillar protein breakdown have been identified as a contributing factor to skeletal muscle atrophy in heart failure patients (17). Although it is presently unclear whether alterations in protein kinetics are a consequence of physical inactivity, it is possible that therapeutic interventions designed to increase physical activity, such as exercise training, may preserve skeletal muscle mass by increasing myofibrillar protein synthesis (3 1). Another contributing factor to the lower daily energy expenditure in cachectic patients was their lower resting energy expenditure.
Resting energy expenditure was lower in cachectic patients by 284 and 147 kcal/day compared with noncachectic and healthy controls, respectively. However, because groups differed with respect to fat-free mass, the principal determinant of resting energy expenditure, we also examined differences in resting energy expenditure after statistical control for fat-free mass. With this adjustment, resting energy expenditure was similar between cachectic patients and healthy controls, whereas a trend toward an elevated resting energy expenditure was found in noncachectic patients. Thus lower resting energy expenditure in cachectic patients compared with healthy controls is principally due to reduced metabolically 'active tissue.
The absence of an elevated resting energy expenditure in cachectic and noncachectic patients compared with healthy controls differs from previous findings (23, 24) but may be explained by the heterogeneity of these groups with respect to weight loss and disease severity. Prior weight loss may explain the absence of an elevated resting energy expenditure in cachectic heart failure patients. Reductions in resting energy expenditure designed to prevent the further depletion of body cell mass are a well-known adaptation to weight loss (12). Thus, in cachectic patients, absence of a hypermetabolic state at rest may be due to weight loss-induced reductions in resting energy expenditure. Although one may question the categorization of cachexia based on the history of weight loss because of shifts in fluid status associated with diuresis, the lower fat mass, fat-free mass, and the fact that weight loss was expressed relative to premorbid body weight suggest that weight loss was primarily the result of reductions in body cell mass and not diuresis-associated reductions in body water.
In noncachectic patients, absence of resting hypermetabolism may be explained by their low to moderate symptom severity, as indicated by New York Heart Association functional class. Noncachectic patients in the present study (n = 13) were primarily classified as New York Heart Association functional classes II (n = 7) and III (n = 5), whereas subjects in our previous study (23) were largely grouped in functional classes III (n = 14) and IV (n = 4). Recent work from our laboratory showed that resting energy expenditure increases in heart failure patients with increasing functional class (18). Thus, although we noted a trend toward an increased resting energy expenditure in noncachectic patients, the examination of more symptomatic patients may be necessary to observe a significant resting hypermetabolism.
Collectively, these findings demonstrate how spurious conclusions can be drawn regarding the presence of elevated daily energy expenditure when only resting energy expenditure is measured.
Tumor necrosis factor-e is a proinflammatory cytokine that causes weight loss in experimental animals (6). Tumor necrosis factor-a is elevated in some heart failure patients (14) and may contribute to weight loss. Thus we examined whether tumor necrosis factor-a was elevated in cachectic heart failure patients and its relationship to energy expenditure. noncachectic heart failure patients. Moreover, no difference in tumor necrosis factor-a was found in the present heart failure cohort when subjects were grouped as cachectic (n = 11; 164 t 101 pg/ml) and noncachectic (n = 5; 404 t 393 pg/ml) according to the criteria used by McMurray et al. (body fat percentage ~27% in males and <29% in females). Thus divergent results between studies are probably not due to the criteria used for grouping subjects as cachectic and noncachectic.
Longitudinal studies are needed to clarify the possible contribution of tumor necrosis factor-a to weight loss in heart failure.
Because no evidence for an elevated daily energy expenditure in cachectic patients was found, we suggest that reduced energy intake accounts for the weight loss in heart failure patients.
Although estimates of energy intake in the present study do not substantiate this hypothesis, the inaccuracy of self-reported intake diaries (10, 25) precludes a thorough testing of this hypothesis.
In agreement with previous findings from our laboratory (lo), noncachectic patients and healthy controls were found to underreport energy intake. Interestingly, however, cachectic patients slightly overestimated dietary energy intake. Although subjects were instructed to record any amount of food that was not consumed during the meal, failure to do so may have contributed to an overestimation of energy intake in cachectic patients. Several factors, including abdominal pain and distension, gastrointestinal hypomotility, and delayed gastric emptying, have been suggested to contribute to anorexia in heart failure patients (20). Further studies that covertly monitor food intake in heart failure patients in response to perturbations in energy balance are needed to examine the regulation of energy intake.
Because of the cross-sectional nature of our study, we cannot rule out the possibility that an elevated daily energy expenditure in the precachectic state contributes to weight loss. The fact that daily energy expenditure was not elevated in noncachectic patients, however, argues against an elevated daily energy expenditure preceding weight loss. A longitudinal examination of changes in energy expenditure and body composition in heart failure patients is needed to fully elucidate the determinants of weight loss. Our results do not support the hypothesis that elevated daily energy expenditure is related to weight loss in heart failure patients.
In fact, daily energy expenditure was lower in cachectic patients due to lower physical activity and resting energy expenditure. We conclude from these findings that inadequate energy intake, not elevated energy expenditure, accounts for the weight loss in heart failure patients. 
